Logo

Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Share this

Roche Reports Results of Satralizumab in P-III SAkuraSky Study to Treat Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Shots:

  • The P-III SAkuraSky study involves assessing of satralizumab (120mg- SC) + baseline immunosuppressant therapy vs PBO + baseline immunosuppressant therapy in ratio (1:1) in 83 patients with NMOSD
  • P-III study results: relapse-free patients @ 48- 96 and 144wks. (89%- 78%- 74% vs 66%- 59%- 49%)- Experienced PDR (20% vs 43%); AQP4-IgG seropositive & seronegative subgroup: experienced a PDR (11% vs 43%) & (36% vs 43%)
  • Satralizumab is a mAb targeting IL-6 receptor and has received Orphan Drug Designation in the US- EU- and Japan plus granted BT designation by the US FDA in Dec 2018 for NMOSD

Click here to­ read full press release/ article

Ref: Roche | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions